Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Length of ICU stay in pooled analysis (patients with an ICU stay, mITT population)

From: Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials

 

Rezafungin

(N = 55)

Caspofungin

(N = 71)

Absolute difference

Relative difference

Unadjusted mean (SD)a, days

16.1 (15.2)

21.6 (18.0)

5.5

1.34 (95% CI 0.96,1.86)

ICU LoS Adjusted mean (95% CI)a LoS, days

17.3 (13.4,20.6)

21.4 (17.3,26.8)

4.1

1.24 (0.89,1.72)

  1. CI, confidence interval; ICU, intensive care unit; LoS, length of stay; mITT, modified intention to treat; SD, standard deviation
  2. aGeneralised linear model, unadjusted or adjusted for mechanical ventilation status; c(C-R)/(C/R), where C is caspofungin and R is rezafungin. The data were log-transformed because of skewing. The estimate is the ratio of geometric means, with values > 1 indicating more time in the ICU in the caspofungin arm
Back to article page

Critical Care

ISSN: 1364-8535